---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-023345"
form_type: "8-K"
ticker: "ENVB"
cik: "0000890821"
company_name: "Enveric Biosciences, Inc."
filed_at: "2026-05-15T12:00:31+00:00"
generated_at: "2026-05-15T12:07:02.044012+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Enveric Biosciences Q1 net loss narrows to $1.6M; cash position improved to $10.3M

## Summary
- Net loss $1.6M ($1.08 loss per share) vs $2.2M ($14.58) in Q1 2025; cash $4.9M at March 31.
- Raised gross $2.8M in Q1; subsequent $1.5M from warrant exercises and $5M upfront from $13.9M private placement.
- As of May 15, cash balance approx $10.3M; expects to fund EB-003 activities into Q1 2027.
- Advancing EB-003 toward IND; new preclinical data including PTSD model with rapid fear response reduction.
- AbbVie withdrew PGR petition against Enveric patent covering bretisilocin; strengthens IP portfolio.

## SEC filing metadata
- accession: 0001493152-26-023345
- form_type: 8-K
- ticker: ENVB
- cik: 0000890821
- company_name: Enveric Biosciences, Inc.
- filed_at: 2026-05-15T12:00:31+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/890821/000149315226023345/0001493152-26-023345-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/890821/000149315226023345/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-023345
- JSON: https://secwatch.observer/filing/0001493152-26-023345.json
- Plain text: https://secwatch.observer/filing/0001493152-26-023345.txt

## Key facts
- Earnings Releases
  Enveric Biosciences, Inc. reported the first quarter ended March 31, 2026 results: net income Net loss attributable to stockholders was $1.6 million, EPS basic and diluted loss per share of $1.08.
  - Period: the first quarter ended March 31, 2026
  - Net income: Net loss attributable to stockholders was $1.6 million
  - EPS: basic and diluted loss per share of $1.08
  - Result: reported results
  source text: Net loss attributable to stockholders was $1.6 million for the first quarter ended March 31, 2026, including $0.1 million in net non-cash expense, with a basic and diluted loss per share of $1.08
  evidence_url: https://www.sec.gov/Archives/edgar/data/890821/000149315226023345/0001493152-26-023345-index.htm
- Earnings Releases
  Enveric Biosciences, Inc. reported the quarter ended March 31, 2025 results: net income net loss of $2.2 million, EPS basic and diluted loss per share of $14.58.
  - Period: the quarter ended March 31, 2025
  - Net income: net loss of $2.2 million
  - EPS: basic and diluted loss per share of $14.58
  - Result: reported results
  source text: as compared to a net loss of $2.2 million, including $0.3 million in net non-cash income, with a basic and diluted loss per share of $14.58 for the quarter ended March 31, 2025
  evidence_url: https://www.sec.gov/Archives/edgar/data/890821/000149315226023345/0001493152-26-023345-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.